Soluble Fiber for Cholesterol: Psyllium, Oat Beta-Glucan, and the Evidence

Psyllium and oat beta-glucan lower LDL through a validated pathway — but only at a dose most people never reach.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not to replace medical care.

In brief: The short version: soluble fiber really does lower cholesterol, but the effect is modest and most people never take enough to get it. The kind that works is the thick, gel-forming fiber in psyllium and oats — not “fiber” in general — and it has to be taken at a real dose, with meals, every single day, before it does much of anything. Used that way it nudges LDL down by a useful but small amount, through a mechanism solid enough that a prescription drug working the same way was shown decades ago to prevent heart attacks. (9) Fiber itself has never been put through that kind of trial, so it earns a place alongside a heart-healthy plan rather than in place of a statin for someone who needs one. It is cheap, safe, and good for blood sugar and digestion on top of cholesterol — which makes it one of the more worthwhile options in this series, as long as you actually take enough.

Lowers LDL Through a Proven Pathway, at a Dose Almost Nobody Reaches

Two facts sit at the center of this article, and they point in different directions.

The first is that soluble fiber’s mechanism is not speculative. Viscous, gel-forming fiber traps bile acids in the intestine; the liver, short on bile acids, pulls cholesterol out of the bloodstream to make more. A prescription drug class — the bile acid sequestrants, including cholestyramine — does the same thing more forcefully, and one of those drugs was shown in a randomized trial in 1984 to cut coronary events. (9) The pathway fiber uses has, in drug form, prevented heart attacks. Fiber itself has never been put through that kind of trial, so its effect on hard outcomes is an inference from the drug class, not a direct result.

The second is that the effect barely engages unless fiber is used correctly. It depends on a viscous, gel-forming fiber (psyllium, oat or barley beta-glucan — not “fiber” in general), at a daily dose near 7 to 10 grams, taken with meals, every day, for months. Miss any of those and the bile acid pathway is only lightly touched. This is why fiber so often appears to “not work”: in most real-world use, it has not actually been administered the way the trials administered it. The gap between taking some fiber and engaging the pathway therapeutically is wider than most people realize, and closing it is most of the practical task.

Find Your Situation

This table maps what the evidence supports for specific profiles; each row is examined below. (1,3,9)

For psyllium, the biomarker evidence is independently strong — the 2018 meta-analysis was formally GRADE-rated moderate to high (1) — even though no direct fiber outcome trial exists. The largest LDL effect tends to appear in people with elevated baseline LDL, low baseline fiber intake, and refined-carbohydrate-heavy diets, where the absorption side of cholesterol balance has the most room to move. (1)

What Soluble Fiber Is, and What It Isn’t

Viscous fiber lowers LDL. Total fiber grams, by themselves, do not.

“Soluble fiber” covers a range of fibers with very different effects. The LDL-lowering action depends specifically on viscosity and gel formation, not merely on whether a fiber dissolves in water. (5) Two foods can list identical fiber grams and produce entirely different cholesterol effects.

Nutrition labels report total fiber, not the viscous, gel-forming fraction that actually lowers LDL. A product can read “high in fiber” while supplying little of the type that engages the mechanism — the same label-versus-evidence gap Article 2 maps. Tracking total grams without identifying viscous fiber tends to produce the appearance of adherence without the result.

How Viscous Fiber Lowers Cholesterol

The mechanism is well-characterized and shares its core with an entire prescription drug class, the bile acid sequestrants (cholestyramine, colesevelam).

Start with the bile acid cycle. The liver makes bile acids from cholesterol and releases them into the intestine after meals to emulsify fat. About 95% of those bile acids are reabsorbed in the lower small intestine and returned to the liver for reuse, so under normal conditions very little cholesterol is lost — the body recycles efficiently.

Viscous, gel-forming fiber dissolves into a thick gel that physically binds bile acids in the intestine. (5) Trapped, they cannot reach their reabsorption sites; they pass into the colon and leave in stool, carrying their cholesterol-derived structure out of the body. The gel works like a sponge that catches bile acids on the way through.

Sensing the shortfall, the liver converts more circulating cholesterol into replacement bile acids, and to get that cholesterol it raises the number of LDL receptors on its surface and clears more LDL from the blood. The result is a lower circulating LDL. That increase in LDL-receptor activity is the same final step through which most LDL-lowering therapies work, statins and PCSK9 inhibitors included, though each reaches it differently.

This is also why fiber and statins are complementary rather than redundant. LDL reflects a balance between how much cholesterol the liver makes and how much is absorbed from the gut; statins reduce synthesis, while fiber acts on the absorption-and-excretion side by depleting the bile acid pool (as do plant sterols and ezetimibe, from Article 6). Using both engages both sides of that balance, so their LDL effects are genuinely additive rather than overlapping.

A secondary mechanism exists: gut bacteria ferment soluble fiber into short-chain fatty acids, which may modestly inhibit the liver’s cholesterol synthesis. (7) That is the gut–heart pathway Article 3 places among the eleven biological routes that supplement claims invoke — plausible, actively researched, but secondary to the established bile acid mechanism and not, on its own, a proven cardiovascular lever.

The Pathway Is Validated by a Drug — but Fiber Itself Has Not Been Tested

This is where fiber separates from most supplements, and where its honest limit also lives.

The bile acid sequestrant class was tested directly. The Lipid Research Clinics Coronary Primary Prevention Trial (1984) randomized 3,806 middle-aged men with high cholesterol to cholestyramine (24 g/day) or placebo. The drug lowered LDL by about 13% beyond diet and cut the rate of coronary death and nonfatal heart attack by 19% — one of the first randomized demonstrations that lowering LDL lowers coronary events. (9) Bile acid sequestration, the exact mechanism fiber uses, has prevented heart attacks in a controlled trial. Fiber engages that same pathway — more gently, and without a trial of its own.

Two honest caveats keep this from being more than it is. First, LRC-CPPT showed its 19% event reduction at a ~13% LDL drop; fiber’s 5 to 10% is smaller, so the proportional benefit it would predict is smaller too. Second, even in that trial, all-cause mortality fell only about 7% and not significantly — LDL-pathway benefit on coronary events is not the same as a proven mortality benefit. Fiber operates on a validated pathway, at lower potency, and has never been tested directly. That is a stronger position than most supplements in this series hold, and it is still an inference rather than a fiber-specific result.

How Much Soluble Fiber Lowers LDL

The psyllium evidence is the most thorough. A 2018 meta-analysis of 28 randomized trials (1,924 participants) found that at a median dose of about 10 grams per day, psyllium lowered LDL cholesterol by 0.33 mmol/L (95% CI −0.38 to −0.27; roughly 13 mg/dL, near 7%), non-HDL cholesterol by 0.39 mmol/L, and apolipoprotein B by 0.05 g/L. (1)

The apoB result matters. As Article 4 introduced, apoB counts atherogenic particles directly — one per LDL particle — so a fall in apoB reflects genuinely fewer harmful particles in circulation, not a reshuffling of cholesterol among the same particles. A supplement that moves apoB, not just LDL-C, is acting on the quantity the disease actually tracks.

In concrete terms the effect is modest: an LDL of 155 mg/dL would typically fall by about 10 to 15 mg/dL, to roughly 140 to 145 — meaningful in the right context, but nowhere near the targets set for high-risk patients, and not enough to normalize LDL on its own for most people. Setting that expectation early is what keeps an honest 7% result from being mistaken for failure.

Oat beta-glucan, the fiber behind oatmeal’s reputation, performs similarly. A 2014 meta-analysis found that at 3 grams a day or more it lowered LDL by about 0.25 mmol/L (roughly 10 mg/dL, near 6%); an independent meta-analysis confirmed comparable effects on LDL, non-HDL, and apoB. (2,3) One bowl of oatmeal supplies only about 2 grams of beta-glucan — below the 3-gram threshold — which is why many people who eat oatmeal regularly see little measurable change: the dose from oats alone is usually too low. (3) Combining sources (psyllium plus oats or barley) is how the effective intake is reached in practice, and barley beta-glucan carries similar evidence while being clinically underused.

The effect is also fully reversible — LDL drifts back toward baseline when fiber intake drops — so unlike a long-acting medication, fiber has to be present consistently to maintain it.

For scale, statins lower LDL far more: in the head-to-head STELLAR trial, common statins reduced LDL by roughly 28–46% (simvastatin), 37–51% (atorvastatin), and 46–55% (rosuvastatin), versus the 5 to 10% range for soluble fiber. (11) These are different magnitudes of intervention, which matters most in patients at high cardiovascular risk.

Both psyllium and oat/barley beta-glucan carry FDA-authorized health claims — a higher regulatory bar than the structure/function language Article 2 examined, requiring significant scientific agreement. The codified thresholds are 7 grams a day of soluble fiber from psyllium and 3 grams a day of beta-glucan from oats or barley. (4) Like the plant sterol claim in Article 6, these rest on LDL-lowering evidence, not on cardiovascular outcome trials of fiber itself.

The Trial Landscape

The biomarker evidence is among the strongest for any supplement in this series; the fiber-specific outcome evidence does not exist; the pathway has outcome validation through a drug. The table shows what is and isn’t in the record.

The pattern is unusual for a supplement: a large, consistent biomarker base including apoB confirmation, an empty cell where a fiber outcome trial would sit, and a drug-class outcome trial validating the pathway. The absence of a fiber trial does not mean fiber has been shown ineffective for events — it means the question has not been asked directly. The Threapleton association, meanwhile, is for total dietary fiber and is observational, carrying the healthy-diet confounding Article 1 examined: people who eat more fiber differ in many ways from those who eat less. Pathway validation through cholestyramine is meaningful, but it is not the same standard of proof as a direct trial — a distinction that matters most in high-risk patients.

Where Guidelines Stand

Major cholesterol guidelines treat viscous soluble fiber much as the evidence does: as a recommended dietary adjunct, not a substitute for drug therapy. The 2022 ACC expert consensus lists viscous soluble fiber — alongside phytosterols — among the dietary adjuncts that may be considered for lowering atherogenic cholesterol, within the heart-healthy diet that guidelines treat as foundational both before and alongside statins. (12) US and European guidance agree on the shape of it: diet can add meaningful LDL lowering and complements pharmacotherapy, but it does not replace the drugs in patients who need larger reductions. That an endorsed adjunct still carries only surrogate-level evidence is not a contradiction — guidelines recommend fiber because its modest LDL effect is real, safe, and mechanistically validated, not because a fiber outcome trial was ever run. That is the line this article draws as well — fiber has a real, endorsed place in cholesterol management, and that place is adjunctive.

The Strongest Case for Fiber, and Its Limits

The serious case for soluble fiber is genuinely strong, and worth stating at full strength. LDL is causally tied to atherosclerosis. Fiber lowers it (and apoB) through bile acid sequestration — a mechanism that, in drug form, reduced coronary events in a randomized trial. (9) Fiber is inexpensive, very safe, and carries real secondary benefits for blood sugar, satiety, and bowel function that single-target supplements do not. Among the categories in this series, that is about as good as the non-drug evidence gets.

Its limits are equally honest. The LDL effect is small — 5 to 10%, a fraction of a statin’s — so even granting proportional benefit, the expected absolute risk reduction is modest. The outcome evidence is borrowed from a drug, not generated for fiber. And the effect only exists at a dose and consistency most people never reach, so the gap between potential and realized benefit is unusually wide here.

That combination points to the one clinical concern worth stating plainly: the danger with fiber is rarely toxicity — it is treating a 5 to 10% LDL reduction from a supplement as equivalent to the protection delivered by therapies that have actually been shown to prevent heart attacks and strokes in high-risk patients. A lab value improves; whether the protection follows, at this magnitude, has not been demonstrated for fiber directly. Fiber is real infrastructure for a long-term strategy. It is not a substitute for a proven therapy in someone who needs one.

Getting to a Therapeutic Dose

The limiting factor is implementation, not biology. Below a threshold of roughly 7 to 10 grams of viscous soluble fiber a day, the mechanism is only partly engaged and a measurable LDL change is unlikely; that threshold is the amount that meaningfully disrupts daily bile acid recycling, and it matches the FDA’s 7-gram psyllium claim and the ~10-gram median in the psyllium trials. (1,4)

Values are approximate and vary by product and preparation. (8) Reaching 7 to 10 grams a day generally means assembling sources deliberately across meals rather than relying on one. More than 90% of Americans fall short of recommended total fiber intake — before viscous fiber is singled out at all. (8)

This is why fiber so often appears to fail. Sprinkling psyllium occasionally, or eating one daily bowl of oatmeal, delivers a dose and pattern that no randomized trial has shown to lower LDL. In that situation the intervention has not failed; it has not been administered. In the trials that did show an effect, the dose was therapeutic, taken with meals, and sustained daily for weeks to months — because bile acid secretion happens with every meal, and intermittent intake lets the cycle return to baseline between exposures, behaving more like no intervention than a partial one. Two of the most common reasons fiber doesn’t work are dose below threshold and a fiber that doesn’t actually form a gel.

Fiber and Medication Absorption

The same gel-forming property that traps bile acids can also bind co-administered medications and reduce their absorption. This is a well-documented clinical interaction, not a theoretical one, and the standard guidance is to separate fiber supplements from medications by about two hours. The risk is greatest when fiber is added after a medication dose has already been stabilized, because any drop in absorption then shifts a previously steady drug level downward.

Drugs with a narrow therapeutic window — where the gap between an effective and a problematic level is small — deserve particular attention, including levothyroxine, digoxin, lithium, carbamazepine, and warfarin. Levothyroxine is especially sensitive and is usually taken on an empty stomach well before food, so coordinating it with fiber takes real planning. For anyone on these or other prescription medications, the fiber-and-medication schedule is worth working out with the prescriber rather than alone. The interaction is manageable — usually through timing and a couple of hours of separation — but it is the single most important piece of safety information in this article.

Safety and Side Effects

Soluble fiber has an excellent safety record, with no established pattern of long-term toxicity.

Gastrointestinal symptoms — bloating, gas, abdominal discomfort — are the most common reason people stop. They are dose-related and most pronounced when intake rises quickly; they reflect the gut adapting to more fermentable substrate rather than harm, and they typically ease over a few weeks as intake is built up gradually. Symptoms that persist past the adjustment period can reflect intolerance to a particular fiber, and switching between psyllium and beta-glucan resolves it for some people.

Psyllium absorbs a lot of water and needs to be taken with enough fluid; product labeling advises a full glass of water with each dose, and inadequate fluid has been linked to rare cases of esophageal or intestinal obstruction. For people with esophageal narrowing, significant swallowing difficulty, or serious gastrointestinal motility disorders — and during pregnancy or breastfeeding — psyllium is best used only with clinician guidance.

High fiber intake can, in theory, reduce absorption of minerals such as iron, zinc, and calcium, but for people eating varied diets this is rarely clinically meaningful. (7) The main exception worth raising with a clinician is someone with marginal nutritional status or existing iron deficiency.

Beyond Cholesterol: Glycemic Control and Other Benefits

Fiber’s value extends past LDL, which is a genuine advantage over single-mechanism supplements.

The most important secondary effect is glycemic. The same viscous gel that slows bile acid reabsorption also slows carbohydrate digestion and glucose uptake, blunting post-meal blood sugar rises; randomized trials show meaningful reductions in fasting glucose and HbA1c — the marker of average blood sugar over the prior two to three months — with adequate soluble fiber in people with type 2 diabetes or prediabetes. (7) For someone managing both cholesterol and blood sugar, a single dietary change addresses both, which is what makes fiber one of the more efficient interventions in metabolic syndrome, where risk factors cluster. (7)

Fiber also adds volume and fullness to meals without adding calories, which can help with the appetite side of weight management. (7) There is some evidence of a small blood pressure reduction with psyllium, though it is less consistent than the cholesterol data. And for the growing number of people on GLP-1 receptor agonists such as semaglutide and tirzepatide, adequate fiber can help with bowel regularity — though pairing high-dose fiber with those drugs can add gastrointestinal side effects, so it is best titrated with a clinician.

Where Soluble Fiber Fits, and What It Costs

Soluble fiber sits in the middle of the LDL-lowering spectrum: stronger than general diet change for LDL specifically, weaker than pharmacotherapy in both magnitude and outcome evidence, and additive with both.

On cost, psyllium is among the least expensive options for a modest LDL reduction, with glycemic and digestive benefits plant sterols do not offer.

The main barrier with fiber is not cost. It is consistency.

Two Example Patients

Both are composites — not real individuals — built from the populations and trials reviewed here, meant to show how the same product fits differently, not to direct any reader’s decision.

Patient A is 54, with prediabetes (HbA1c 6.2%), LDL 148 mg/dL, low-to-moderate cardiovascular risk, and no medications; her physician has recommended lifestyle changes before any drug. This is close to the profile where the evidence for fiber is strongest: a real LDL effect at a therapeutic dose (1) and a real glycemic benefit from the same intervention, (7) in someone whose risk is low enough that a 5 to 10% LDL reduction is meaningful at the margin without displacing anything more important. What that would look like in practice — a viscous fiber at therapeutic dose, with meals, sustained for a couple of months, then a repeat lipid panel and HbA1c — and whether to pursue it at all are reasonable things for her to work through with her physician.

Patient B is 68, with a heart attack five years ago, type 2 diabetes, and LDL 95 mg/dL on a moderate-intensity statin; his cardiologist has raised adding ezetimibe, and he wants to use psyllium instead. His situation falls outside that profile in every direction. His risk is high, the evidence points to more intensive LDL lowering, and ezetimibe carries direct outcome evidence in his exact population — post-acute-coronary-syndrome patients on a statin (the IMPROVE-IT trial, covered in Article 6). Fiber’s 5 to 10% reduction is well below ezetimibe’s, and its cardiovascular evidence is pathway inference rather than a trial in patients like him. Fiber could still be part of his diet, but the question that matters is whether choosing it instead of the proven add-on his cardiologist proposes would substitute a smaller, indirectly evidenced intervention for a larger, directly evidenced one. The hazard there is not toxicity; it is false reassurance — and the decision belongs with him and his cardiologist.

Common Misconceptions

“Total fiber on a label predicts the cholesterol effect.” It doesn’t. Only viscous, gel-forming fiber engages the bile acid mechanism. (5) A “high-fiber” cereal can be mostly insoluble fiber and move LDL very little. Type matters more than gram count.

“Eating oatmeal is enough.” One bowl provides about 2 grams of beta-glucan — below the 3-gram threshold in the FDA claim and below the dose at which trials measured an effect. (3,4) Most people who eat oatmeal regularly are not reaching a therapeutic dose from oats alone.

“Fiber works the same whenever it’s taken.” It doesn’t. The mechanism needs bile acids present in the intestine, which happens with meals; fiber taken on an empty stomach between meals engages it poorly.

“Occasional or weekend fiber is enough.” It isn’t. The bile acid cycle resets between exposures, so intermittent intake behaves more like no intervention than a partial one.

“Fiber and a statin are alternatives.” They aren’t. They act on different sides of cholesterol balance — synthesis (statin) and absorption (fiber) — so they are complementary, and their LDL effects are not in the same magnitude class.

“Fiber’s benefits are limited to cholesterol.” They aren’t. Glycemic control, satiety, bowel function, and microbiome support are part of the profile, (7) which is one of fiber’s genuine advantages over single-mechanism supplements.

The Bottom Line

Soluble fiber lowers LDL by about 5 to 10% when it is used the way the trials used it: the right viscous fiber, at a therapeutic dose, with meals, every day, for months. (1) Used the way most people use it, it produces little measurable change — not because it failed, but because it was never administered at the dose and consistency that engage the mechanism.

The biology is real and the LDL effect is real. The bile acid pathway fiber uses has, in drug form, reduced coronary events in a randomized trial of cholestyramine. (9) The fiber-specific trial has never been run, so the cardiovascular benefit rests on drug-class evidence rather than a direct test — and a 5 to 10% LDL reduction does not stand in for pharmacotherapy in patients who need meaningful risk reduction.

Across Articles 4 through 7 the same ladder keeps descending. Omega-3 therapy has one formulation with FDA cardiovascular drug approval. CoQ10 has one positive heart failure trial, never replicated. Plant sterols have no outcome trial and a health claim built on a biomarker. Soluble fiber shares that health-claim category, but with stronger pathway validation than any of them — a hard-outcome trial of a drug that works the same way. (9) What distinguishes fiber is less the strength of its evidence than the size of the gap between its potential and the way it is typically used. Statins are high-potency, precisely targeted pharmacotherapy with direct outcome evidence; fiber is low-potency metabolic infrastructure with smaller effects and broader metabolic benefits. They are different tools for different roles, and fiber was never a smaller statin. Closing the gap between “I take fiber” and “I am dosing fiber to engage the pathway” is the practical work this article describes.

Article 8 turns to niacin — a supplement that raised HDL more dramatically than almost anything ever tested, failed to reduce cardiovascular events in two large trials, and increased harm. It is the clearest case in the series of a marker improving while outcomes did not.

Key Terms

ApoB (apolipoprotein B). A protein carried on each LDL particle; counting it counts atherogenic particles directly, a more precise risk measure than LDL-C alone. Psyllium modestly reduces apoB alongside LDL. (1)

Beta-glucan. A viscous soluble fiber in oats and barley responsible for their cholesterol-lowering effect and the subject of an FDA-authorized health claim at 3 g/day. (4)

Bile acid sequestration. The mechanism by which viscous fiber traps bile acids in the intestine, preventing reabsorption and forcing the liver to draw on circulating LDL to make replacements.

Cholestyramine. A prescription bile acid sequestrant — fiber’s drug-class equivalent — shown to reduce coronary events in the Lipid Research Clinics Coronary Primary Prevention Trial. (9)

Enterohepatic circulation. The recycling loop in which bile acids are secreted into the intestine and reabsorbed back to the liver; viscous fiber interrupts it, forcing net cholesterol excretion.

FDA-authorized health claim. A disease-risk-reduction statement permitted on labels based on significant scientific agreement — a higher bar than structure/function language. Authorized for psyllium and oat/barley beta-glucan on the basis of LDL lowering, not outcome trials. (4)

HbA1c. A blood test reflecting average blood sugar over the prior two to three months; adequate soluble fiber produces meaningful HbA1c reductions in prediabetes and type 2 diabetes. (7)

LDL-receptor upregulation. The liver’s increase in LDL-clearing receptors when cholesterol availability drops — the final common step through which fiber, statins, and PCSK9 inhibitors all lower LDL.

Narrow therapeutic window. A drug for which the gap between effective and problematic doses is small. Levothyroxine, digoxin, lithium, carbamazepine, and warfarin are examples sensitive to fiber-related absorption changes.

Psyllium. The husk of Plantago ovata seeds; one of the most concentrated viscous soluble fibers and the most studied for LDL reduction, supplying roughly 5 g of soluble fiber per tablespoon.

Short-chain fatty acids (SCFAs). Metabolites from bacterial fermentation of soluble fiber (butyrate, propionate, acetate) that may modestly inhibit hepatic cholesterol synthesis. (7)

Soluble fiber. Fiber that dissolves in water; the cholesterol-lowering effect is specific to the viscous, gel-forming subset, not all soluble fibers. (5)

Surrogate endpoint. A measurable marker, such as LDL, used as a proxy for clinical outcomes; LDL is a well-validated surrogate, but direct outcome evidence from isolated fiber-supplementation trials does not yet exist.

Viscosity. The gel-forming property that determines a fiber’s ability to trap bile acids — a better predictor of cholesterol-lowering than fiber content alone. (5)

References

1. Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018;108(5):922–932.
2. Ho HVT, Sievenpiper JL, Zurbau A, et al. The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br J Nutr. 2016;116(8):1369–1382.
3. Whitehead A, Beck EJ, Tosh S, Wolever TMS. Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2014;100(6):1413–1421.
4. US Food and Drug Administration. Health claims: soluble fiber from certain foods and risk of coronary heart disease (CHD). 21 CFR 101.81.
5. McRorie JW, McKeown NM. Understanding the physics of functional fibers in the gastrointestinal tract: an evidence-based approach to resolving enduring misconceptions about insoluble and soluble fiber. J Acad Nutr Diet. 2017;117(2):251–264.
6. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ. 2013;347:f6879.
7. Anderson JW, Baird P, Davis RH Jr, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67(4):188–205.
8. US Department of Agriculture and US Department of Health and Human Services. Dietary Guidelines for Americans, 2020–2025. 9th ed. 2020.
9. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351–364.
10. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). N Engl J Med. 2018;378(25):e34.
11. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92(2):152–160.
12. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366–1418.

HeartBuddi • Your heart. Own it.